Kornimate/medical-research-clean huggingface dataset:
erector spina block or parasternal block plus chest tube wound infiltration for cardiac surgeries

Conditions: Postoperative Pain; Postoperative Atelectasis; Analgesia

Summary: pain management is important after coronary artery bypass graft (cabg) surgery. intravenous morphine is the gold standard for pain relief, but its sedation, cough suppression and decreased bowel movements limit its use. analgesia with regional methods after surgery provides effective analgesia by reducing morphine consumption. in this study we have planned to compare the erector spina plane block with parasternal block +local infiltration to chest tube areas.

patients who will undergo open heart surgery will be included in this study. pain management is important after coronary artery bypass graft (cabg) surgery. poorly controlled postoperative pain can trigger myocardial ischemia, increase catecholamine levels, result in increased complications such as stroke and bleeding, and increase the risk of pneumonia. intravenous morphine is the gold standard for pain relief, but its sedation, cough suppression and decreased bowel movements limit its use. for this reason, regional methods are gaining importance in pain treatment. after cardiac surgery. both sternotomy and bilateral chest tubes are the most painful interventions during cardiac surgeries. parasternal block can be a good alternative in the treatment of pain in cabg surgeries. in parasternal application, the aim is to anesthetize the nerves innervating the sternum between the pectoral muscle and the intercostal muscle by holding the probe in the parasagittal plane on the lateral side of the sternum under usg guidance. patients who will undergo open heart surgery will be included in this study. the patients will be divided into two groups, and in group 1, before general anesthesia is given, bilateral espb will be performed at the 4-6th thoracic level in the prone position, and then routine general anesthesia will be performed (at this stage, the patients will be given sedation to prevent them from feeling pain). after endotracheal intubation, in group 2, a parasternal block will be performed from the lateral sternum. at the end of the surgery, local anesthetic infiltration will be perform to the tube sites. general anesthesia and surgical procedures will be performed routinely in both groups. in the intensive care unit patients will be monitored for pain levels, intubation duration, whether there is atelectasis in the lungs, and the need for reintubation. pain assessment will be evaluated with the behavioral pain score while the patients are intubated and with the visual pain scale after extubation. whether atelectasis has developed will be evaluated with ultrasonography at the 12th and 24th hours postoperatively

Eligibility criteria:
inclusion criteria: 1. patients who will undergo open heart surgery 2. patients who agreed to participate in the study- exclusion criteria: 1. patients who do not agree to participate in the study 2. patients with chronic lung disease 3. patients with d. mellitus

Keywords: cpbgs postop analgesia espb parasternal block local anesthetic
treatment of intracerebral hemorrhage in patients on non-vitamin k antagonist

Conditions: Intracerebral Hemorrhage

Summary: novel, non-vitamin k antagonist oral anticoagulants (noac) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor xa-inhibitors apixaban and rivaroxaban. intracerebral hemorrhage (ich) is the most feared complication of noac treatment (noac-ich). outcome of noac-ich can be devastating and is a major cause of death and disability. there is no proven treatment for noac-ich. hematoma expansion (he) is associated with unfavorable outcome. tranexamic acid (ta) is an anti-fibrinolytic drug that is used in a number of bleeding conditions other than ich.


Eligibility criteria:
inclusion criteria: * acute intracerebral hemorrhage (symptom onset \<12h) * prior treatment with a novel direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban; last intake \<48hours or proven noac activity by relevant coagulation assays) * age \>18 years, no upper age limit * informed consent has been received in accordance to local ethics committee requirements exclusion criteria: * severe pre-morbid disability (modified rankin scale \>4) * anticoagulation with vitamin k antagonists (vka) (recent intake) * secondary intracerebral hemorrhage (e.g. arteriovenous malformation (avm), tumor, trauma) note it is not necessary for investigators to exclude underlying structural abnormality prior to enrolment, but where an underlying structural abnormality is already known, these patients should not be recruited. * glasgow coma scale \<5 * pregnancy * planned neurosurgical hematoma evacuation within 24 hours (before follow-up imaging) * pulmonary embolism/deep vein thrombosis within the last 2 weeks.

Keywords: tranexamic acid noac direct oral anticoagulant (doac) direct oral anticoagulants non-vitamin k antagonist oral anticoagulants
long-term follow-up of fingolimod phase ii study patients

Conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Summary: this study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in fty720d2201 (d2201). no study drug was given or required. participants were required to be assessed at one or two visits, preferably at the original study site, but the option to be interviewed via phone or seen at home was provided. information was gathered also on deceased participants. assessments were performed only once within an 8 week period and included medical history, multiple sclerosis (ms) and multiple sclerosis disease modifying therapy (ms dmt) history, expanded disability status scale (edss), magnetic resonance imaging (mri), and multiple sclerosis functional composite (msfc).

this was a multicenter follow-up study of patients originally enrolled in the phase 2 d2201 study. patients did not receive any protocol specified treatment. the original d2201 study sites who agreed to participate in this study were required to locate their patients who were randomized in study d2201 and asked them to return for a 10-year assessment, regardless of their current treatment status. locating the patient may have required the use of search and advertising strategies to find those patients currently lost to follow-up, in accordance with local privacy legislation. patients currently being followed within study fty720d2399 (nct01201356) were asked to participate in study fty720d2201e2 and if patients gave consent, were enrolled concurrently in both studies.

Eligibility criteria:
inclusion criteria: * written informed consent must be obtained before any assessment is performed. * randomized in study fty720d2201 and received at least one dose of study drug. exclusion criteria: * none

Keywords: multiple sclerosis, ms, rrms, relapsing forms of multiple sclerosis, fingolimod, fty720, gilenya
safety & effectiveness of autologous regenerative cell therapy on pain & inflammation of osteoarthritis of the shoulder

Conditions: Osteoarthritis

Summary: this is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with osteoarthritis of the shoulder. follow-up will consist of a larger sample including 4,000 patients.

this is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with osteoarthritis of the shoulder. follow-up will consist of a larger sample including 4,000 patients. patients will be treated for osteoarthritis (oa) of the shoulder due to degeneration or chronic injury. they will be treated with autologous stromed obtained by the adipose ultrasonic cell recovery unit (aucru) and platelet rich plasma (prp) processed by the regenlab (regenkit bct-3) prp product each as direct injections to the affected joints. patient outcomes will be tracked with laboratory tests for inflammation markers, the dash and spadi questionnaires and a follow up mri at various endpoints to 6 months. sf-36 forms (a quality of life measure) and numerical ratings scales (nrs) will also be used to assess safety and efficacy of treatment, as well as any reduction in patient medication and/or delay in pending shoulder planning/replacement therapy.

Eligibility criteria:
inclusion criteria: 1. patients with indication of osteoarthritis. can be from degeneration or chronic injury. 2. patients range from 18-90 years of age. 3. patients must be able to comply with treatment plan, laboratory tests and periodic interviews. 4. patients with adequate renal function, creatinine ≤ 1.5 mg/dl. 5. patients with adequate cardiac and respiratory function. 6. patients with adequate blood coagulation activity, pt(inr) \< 1.5, aptt 7. patients must have adequate immune system function, with no known immunodeficiency disease. 8. greater than 6 months shoulder pain with the index side (left or right shoulder). exclusion criteria: 1. neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision 2. presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke).. 3. diagnosis of a transient ischemic attack in the 6 months prior to screening. 4. patients infected with hepatitis b, c or hiv. 5. patients with body mass index (bmi) \> 40kg/m2 6. presence of active infection. 7. any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study. 8. conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to: 1. treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis 2. corticosteroid injection at treatment site within 1 month 3. consistent use of nsaids within 48 hours of procedure.
vitalscan mcg rule-out multi-centre pivotal study - uk

Conditions: Acute Coronary Syndrome

Summary: the study is a prospective multi-centre observational study to evaluate a portable magnetocardiograph device for the rule-out of acute coronary syndrome (acs) in patients who present to the emergency department with chest pain and other symptoms consistent with acs.

few, if any, studies have evaluated the rule-out (r/o) of non-st-segment elevation (nste) acs which requires the sensitivity and negative predictive value (npv) of the test to approach 100%. an alternative triage approach, utilizing a portable magnetocardiography (mcg) instrument in the emergency setting, may lead to a more accurate r/o for nstemi, ua, and clinically significant non-acs coronary artery disease (cad), in patients presenting to the ed with chest pain. mcg in the emergency setting is a new use of this non-invasive technique and may serve as an adjunctive aid that can improve cardiac triage for nste acs and clinically significant cad.this raises the research question of whether mcg may be useful for the early triage of patients with acute chest pain. in the study protocol, a clinical evaluation is defined that will assess the ability of a portable mcg instrument, using a fixed algorithm, to r/o acs, with improved safety (i.e. \<\< 2% false negative rate) in patients presenting to an emergency setting with chest pain.

Eligibility criteria:
inclusion criteria: * patient presents to the ed with chest pain syndrome of suspected cardiac origin (i.e. symptoms consistent with acs) * 18+ year old male or female * patient is willing and able to give written informed consent exclusion criteria: * st-segment elevation mi (stemi) * clear non-ischaemic cause for symptoms (e.g. trauma) * haemodynamic instability on admission (e.g. bp\>220mmhg systolic \& \>110mmhg diastolic, \ 160bpm) * ventricular tachycardia or fibrillation that cannot be treated effectively * atrial fibrillation * thoracic metal implants * pacemaker or internal defibrillator * pregnancy (if after 20-week period)\* or lactation * patient unable to lie down (i.e. supine position) or stay still on the examination bed * patient unable to understand the informed consent process and/or has a poor understanding of english (e.g. english-speaking relative/translator not available) * patient unable to comply with the requirements of the protocol

Keywords: cardiovascular diseases heart diseases myocardial ischemia nste acs nstemi unstable angina pectoris coronary artery disease
maternal attachment and depression anxiety score evaluation in covid-19 positive pregnant women

Conditions: Covid19; Depression, Anxiety; Pregnancy Related

Summary: maternal attachment, edinburgh depression scoring, and postpartum anxiety scale are evaluated in patients with covid-positive pregnancies in the 3rd month after birth.

maternal attachment, edinburgh depression scoring and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth. the results will be compared with the results of covid-negative pregnant women who gave birth in the same period.

Eligibility criteria:
inclusion criteria: * covid -19 positive and negative pregnant women * have no psychiatric illness * not using antidepressants or antipsychotic drugs exclusion criteria: * women with psychiatric illness * using antidepressants or antipsychotic drugs * not pregnant * adolescent pregnancy
impact of hepatitis b virus on inflammatory bowel disease

Conditions: Inflammatory Bowel Disease (IBD); Hepatitis B Virus

Summary: the goal of this observational retrospective study is to assess the impact of hepatitis b virus (hbv) infection on the clinical course and outcomes of inflammatory bowel disease (ibd) in egyptian patients. researchers will compare the ibd extent, location, severity, and behavior between ibd patients with and without hbv infection. participants will be subjected to history-taking (history of hospital admission and disease flare, surgical history, medication history, follow-up duration, and mortality), clinical examination, laboratory investigations, abdominal ultrasonography, and endoscopic examination.


Eligibility criteria:
inclusion criteria: * male or female patients older than 18 years. * patients with ibd are diagnosed by clinical, radiological, endoscopic, and histological criteria. exclusion criteria: * patients aged \< 18 years * unwilling to participate in our study

Keywords: hepatitis b virus inflammatory bowel disease course
the efficacy and safety of lacidipine and amlodipine once-daily treatment in hypertensive adult patients

Conditions: Uncomplicated Hypertension; Hypertension; Essential

Summary: the sustained reduction in elevated blood pressure and lower incidence of adverse events of lacidipine may provide additional benefits for hypertension patients than other ccbs (calcium channel blockers). this study is to compare the efficacy and safety of lacidipine with amlodipine, the most widely used ccb in taiwan, in hypertensive patients.


Eligibility criteria:
inclusion criteria: * informed consent written prior to the recruit into the study * male or female subjects * patients with diagnosis of essential, uncomplicated hypertension * after one to two weeks washout period, patients showing, systolic blood pressure equal or lager than 160mmhg or diastolic blood pressure equal or lager than 90mmhg subject could be enrolled in one of the following state: 1. patients previously untreated for hypertension; 2. intolerant or not responding to their current therapy; 3. patients controlled under their previous therapy but who can safely and agree to be switched to the trial therapy could clinically feasible for mono-therapy for hypertension control. exclusion criteria: * any form of secondary hypertension * history of malignant hypertension or evidence of accelerated hypertension * myocardial infarction within 3 months * unstable angina pectoris * congestive heart failure * atrial fibrillation * life threatening arrhythmia * history of cerebrovascular accident * clinically relevant renal disease; defines if serum creatinine equal or lager than 1.5 mg/dl * liver function abnormal: glutamic-oxalacetic transaminase lager than 2 times of upper limit normal or glutamic-pyruvic transaminase lager than 2 times of upper limit normal * existence of any serious systemic disease * allergic history to the compounds of both study medication * can not comply the study protocol or misunderstand the informed consent form * other diseases which treated by calcium channel blockers

Keywords: essential hypertension amlodipine blood pressure lacidipine
use of 50% nitrous oxide / 50% oxygen premix in primary care dental centers

Conditions: Dental Cares

Summary: a 50% nitrous oxide / 50% oxygen premix is administrated to the patient during the realization of dental cares. this openly clinical trial is done in 36 french primary care dental centers, especially on anxious and phobic patients but also on infants or mental deficient adults. at least 480 patients will be included in this clinical protocol.


Eligibility criteria:
inclusion criteria: * anxious and/or phobic patients having a vomiting reflex * very young children requiring selective dental cares * mental deficient patient * patient having specific phobia linked to the dental care to be done * patient from 1 year old * asa 1 or asa 2 patient * existing of efficient contraception exclusion criteria: * asa 3 or asa 4 patient * patient already treated without using kalinox's sedation * patient already included in this protocol in a delay lower than 7 days * contraindication linked to the experimental product * kalinox's inhalation duration higher than 1 hour * pregnant or breast-feeding women
prostate cancer screening for people at genetic risk for aggressive disease, patrol study

Conditions: Prostate Carcinoma

Summary: this study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

outline: participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.

Eligibility criteria:
inclusion criteria: * people with prostates ≥40 years of age * documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk. exclusion criteria: * prior diagnosis of prostate cancer * medical contraindication to any of the study procedures (e.g., prostate biopsy) * for all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy) * prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk * unable to provide written informed consent * unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.
brain-shift monitoring using 3d scanning

Conditions: Craniotomy for Epilepsy and Malignant Tumor Removal

Summary: a prospective non-invasive data/image collection for evaluation of the performance of the advanced scanners 3d scanner during brain surgery. the primary objective is to evaluate the performance of the scanner in determining the brain surface shape over multiple time points during craniotomies (surgical opening into the skull), and present those shapes in full color, with high resolution in all three coordinates of 3d space. a secondary objective is to use the measurements to determine brain shift as a function of time.

the scanner sterilization will largely follow procedures used currently for cameras and microscopes: the scanner will be draped in a disposable drape custom manufactured for the device by a leading instrument drape manufacturer (medline). the drape will be windowed with a sterilized shatterproof plastic optical window. standard hospital procedures will be followed for the disposal of instrument drapes. the drape will be sterile and wrapped in the conventional manner, and the drape itself will be disposable. prior to surgery, the drape, window and frame will undergo the same sterilization procedure as other equipment. if window transparency is compromised during surgery, it can be cleaned with a cleaning agent. the scanner will illuminate the craniotomy region with light for the duration of its use, which may be for the duration of the surgery. the scanner will be anywhere from 8 to 12 inches away from the patient, illuminating the subject's brain by the scanner light for 2 minutes at a time, or continuously, either with or without maximum overhead lighting. for each patient, the duration of obtaining data will last for the duration of the clinical operation procedure. the 3d scanner on and off time would add less than 5 minutes to the procedure, not including measurement time.

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 6 years of age at visit 1. 2. clinically planned for craniotomy, including for malignant tumors, whether awake or under general anesthesia. 3. able to provide written informed consent (and assent when applicable) - by subject or subject's legal representative - and agrees to comply with the requirements of the study. exclusion criteria: 1. language problems that would prevent from properly understanding instructions. 2. requirement of an interpreter. 3. patients who are excluded from consideration for the clinical operation are therefore excluded from the research study. 4. special populations: pregnant women, prisoners.
the impact of stent deployment techniques on clinical outcomes of patient treated with the cypher® stent (s.t.l.l.r.)

Conditions: Coronary Stenosis

Summary: 1500 eligible patients will be treated with the commercially available cypher® sirolimus-eluting bx velocity™ stent. patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure on the same diseased area of the coronary artery.

geographical miss has been associated with treatment failures after intracoronary radiation therapy. this phenomenon, which is secondary to vascular injury outside the treated segment, was strongly correlated with the development of restenosis at the edges of the treated coronary segment. the european and canadian sirius trials (e and c-sirius) randomized 350 patients with similar baseline characteristics of the us sirius study. operators used shorter post-dilatation balloons and direct stented 27% of the patients, achieving a 4.0% tlr rate and a 5.1% in-lesion binary restenosis. these somewhat superior results support the concept that refinement in deployment techniques may further improve clinical outcomes of drug-eluting stents.

Eligibility criteria:
inclusion criteria: * diagnosis of de novo stenosis in major coronary artery * can be treated with stents * candidate for bypass exclusion criteria: * recent, severe mi * prior brachytherapy * impaired left ventricle function * heart transplant recipient * impaired renal function * disease in vein grafts from previous bypass * similar treatment within the last 30 days

Keywords: myocardial ischemia coronary disease heart disease coronary stenosis [mesh heading: c14.280.647.250.285]